The burgeoning landscape of medication for weight management and type 2 glucose intolerance is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant variations in their pharmacological profiles and clinical trial results are emerging… Read More

Emerging in the field of excess body fat treatment, retatrutide presents a distinct method. Unlike many current medications, retatrutide functions as a dual agonist, concurrently targeting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. This dual activation promotes various beneficial effects, like enhan… Read More